2023 World Conference on Lung Cancer (Posters)-EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis

EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis - PDF(Abstract)

Back to course

Pdf Summary

This case report discusses the successful treatment of a patient with advanced lung cancer and multiple metastases, including brain metastasis, using aumolertinib. The patient, a 63-year-old female with a history of hypertension, was initially diagnosed with left lung adenocarcinoma (stage IV), mediastinal lymph node metastasis, brain metastasis, bone metastasis, and bilateral pulmonary metastasis, with an EGFR L858R mutation.<br /><br />The patient was initially treated with osimertinib and denosumab, which resulted in significant improvement in foot pain and delayed the need for radiotherapy. However, due to economic reasons and the high permeability of aumolertinib in the blood-brain barrier, the treatment was changed to aumolertinib (110mg Qd po). The patient responded well to the treatment, with no obvious adverse reactions and a progression-free survival (PFS) of more than 36 months.<br /><br />The case highlights the potential of aumolertinib monotherapy in achieving positive outcomes for advanced lung adenocarcinoma patients with multiple metastases, including brain metastasis. This treatment option offers a balance between efficacy and safety, allowing for a delay in the timing of local treatments for brain and bone metastases and improving the patient's quality of life.<br /><br />Overall, the findings suggest that aumolertinib could be a valuable therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutations, particularly those with multiple metastases, including brain metastasis. The study emphasizes the importance of optimizing treatment strategies for this patient population, given their poor prognosis and rapid disease progression.

Asset Subtitle

Xiu Shan

Meta Tag

Speaker Xiu Shan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung cancer

metastases

brain metastasis

aumolertinib

advanced adenocarcinoma

EGFR mutation

osimertinib

denosumab

progression-free survival

non-small cell lung cancer